Evidence map›Paper›PMID 26813801›Full record

ArticleVaccine2016

Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11.

Mark G Thompson, Allison Naleway, Alicia M Fry, Sarah Ball, Sarah M Spencer, Sue Reynolds, Sam Bozeman, Min Levine, Jacqueline M Katz, Manjusha Gaglani

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 4 pooled it
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 4 syntheses or guidelines pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Comparison of the immunogenicity of adjuvanted and conventional egg-based quadrivalent influenza vaccines among healthcare personnel in Lima, Peru: A randomized controlled trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
    Trial
  6. Enhanced Influenza Vaccines Extend A(H3N2) Antibody Reactivity in Older Adults but Prior Vaccination Effects Persist.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Trial
  7. Trial
  8. Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
    Trial
  9. Trial
  10. Preliminary Findings From the Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE I) Study: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Observational

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Mark G ThompsonEpidemiology and Prevention Branch, Influenza Division/NCIRD/CDC, Atlanta, GA 30333. Electronic address: isq8@cdc.gov.
Allison NalewayThe Center for Health Research, Kaiser Permanente Northwest, Portland, OR 97227.
Alicia M FryEpidemiology and Prevention Branch, Influenza Division/NCIRD/CDC, Atlanta, GA 30333.
Sarah BallAbt Associates, Cambridge, MA 02138.
Sarah M SpencerEpidemiology and Prevention Branch, Influenza Division/NCIRD/CDC, Atlanta, GA 30333.
Sue ReynoldsEpidemiology and Prevention Branch, Influenza Division/NCIRD/CDC, Atlanta, GA 30333.
Sam BozemanThe Center for Health Research, Kaiser Permanente Northwest, Portland, OR 97227.
Min LevineEpidemiology and Prevention Branch, Influenza Division/NCIRD/CDC, Atlanta, GA 30333.
Jacqueline M KatzEpidemiology and Prevention Branch, Influenza Division/NCIRD/CDC, Atlanta, GA 30333.
Manjusha GaglaniDivision of Pediatric Infectious Diseases, Baylor Scott & White Health, Texas A&M HSC COM, Temple, TX 76508.
National Center for Emerging and Zoonotic Infectious Diseases · USKaiser Permanente Center for Health Research · USAbt Global (United States) · USBaylor Scott & White Health · USNational Center for Immunization and Respiratory Diseases · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundRecently, lower estimates of influenza vaccine effectiveness (VE) against A(H3N2) virus illness among those vaccinated during the previous season or multiple seasons have been reported; however, it is unclear whether these effects are due to differences in immunogenicity.

methodsWe performed hemagglutination inhibition antibody (HI) assays on serum collected at preseason, ∼ 30 days post-vaccination, and postseason from a prospective cohort of healthcare personnel (HCP). Eligible participants had medical and vaccination records for at least four years (since July, 2006), including 578 HCP who received 2010-11 trivalent inactivated influenza vaccine [IIV3, containing A/Perth/16/2009-like A(H3N2)] and 209 HCP who declined vaccination. Estimates of the percentage with high titers (≥ 40 and>100) and geometric mean fold change ratios (GMRs) to A/Perth/16/2009-like virus by number of prior vaccinations were adjusted for age, sex, race, education, household size, hospital care responsibilities, and study site.

resultsPost-vaccination GMRs were inversely associated with the number of prior vaccinations, increasing from 2.3 among those with 4 prior vaccinations to 6.2 among HCP with zero prior vaccinations (F[4,567]=9.97, p<.0005). Thirty-two percent of HCP with 1 prior vaccination achieved titers >100 compared to only 11% of HCP with 4 prior vaccinations (adjusted odds ratio=6.8, 95% CI=3.1 - 15.3).

conclusionOur findings point to an exposure-response association between repeated IIV3 vaccination and HI for A(H3N2) and are consistent with recent VE observations. Ultimately, better vaccines and vaccine strategies may be needed in order to optimize immunogenicity and VE for HCP and other repeated vaccinees.

Indexed as

Antibody FormationDose-Response Relationship, ImmunologicHealth PersonnelAdultAntibodies, ViralFemaleHemagglutination Inhibition TestsHumansInfluenza A Virus, H3N2 SubtypeInfluenza, HumanInfluenza VaccinesMaleMiddle AgedProspective StudiesVaccinationVaccines, InactivatedAntibodies, ViralInfluenza VaccinesVaccines, Inactivatedhealthcare personnelhemagglutination inhibition antibodyimmunogenicityinfluenza vaccination

Identifiers

PMID26813801
PMCPMC5218812
OpenAlexW2265205687

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.